Leading Medical Physics Meeting to Feature First Presentations on Clinical Experience with ViewRay's MRIdian Linac
30 Presentations Highlight MRIdian's Growing Role in Cancer Care
CLEVELAND, July 21, 2017 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), makers of the world's only FDA-cleared MRI-guided radiation therapy system with linear accelerator-based delivery, announced today that the company's MRIdian® System is the focus of 30 abstracts selected by the American Association of Physicists in Medicine (AAPM) for presentation during their 2017 Annual Meeting. AAPM is the largest association of medical physicists in the world, and this year's meeting will be held July 30-August 3 in Denver.
MRIdian-focused presentations at this year's meeting include talks and e-posters that highlight topics such as online adaptive radiation therapy, stereotactic body radiation therapy (SBRT), Monte Carlo dose calculation and quality assurance. Abstracts accepted by AAPM were provided by MRIdian users at 5 different centers: University of California, Los Angeles; University of Miami; Washington University in St. Louis, Mo.; Henry Ford Health System; and University of Wisconsin in Madison, Wis.
Additionally, in ViewRay's booth #4009, MRIdian users from University of California, Los Angeles, University of Miami, Washington University, University of Wisconsin and Henry Ford Health System will present on their firsthand experience. Topics to be addressed include the benefits of low-field MRI, plan quality assurance for adaptive radiation therapy and system implementation and commissioning.
Noteworthy in-booth talks include the first presentations on clinical experience with ViewRay's second generation system, MRIdian Linac, given by clinicians from Henry Ford Health System, who recently began MRIdian Linac patient treatments. The Henry Ford team will present on their commissioning experience and the system's imaging capabilities.
"We're excited to be treating with MRIdian Linac and believe it's one of the most significant advances in radiation oncology in decades," said Dr. Indrin Chetty, Ph.D., Professor and Director of the Division of Medical Physics, Department of Radiation Oncology at Henry Ford Health System. "We have been extremely impressed with MRIdian's image quality and speed of treatments. Moreover, the dose calculation accuracy has shown excellent agreement against measurements over a range of benchmark cases."
Clinical applications experts from ViewRay will also be available in the booth to demonstrate planning and delivery functionality of the system. The demos will showcase patient cases illustrating MRIdian image quality and industry-leading Monte Carlo dose calculation to support an on-table adaptive radiation therapy workflow.
For a full schedule of in-booth presentations, and AAPM oral and poster presentations on MRIdian and MRIdian Linac, please visit http://www.viewray.com/aapm_2017.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® and MRIdian Linac radiation therapy systems. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to presentations to be made at the AAPM 2017 Annual Meeting. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the MRIdian linac, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
SOURCE ViewRay, Inc.
Share this article